	March 31, 2021		December 31, 2020
Equity investments at fair value	$	633	$	477
Equity investments under measurement alternative		11,450		11,392
Debt securities classified under available-for-sale method		—		2,500
Total other investments	$	12,083	$	14,369

Unrealized gains recognized in other expenses, net during the three months ended March 31, 2021 on equity investments still held at March 31, 2021 is $300 (2020 – loss of $1,534). There were no impairments or adjustments to equity investments under the measurement alternative for the three months ended March 31, 2021 and March 31, 2020.

The Company collected a cash settlement of its only debt security classified under available-for-sale method instrument with the lender prior to its contractual maturity for $2,500 in February 2021.

As of March 31, 2021, there are no changes to the status of the Company’s assessment of its joint ventures with Anheuser-Busch InBev (“AB InBev”) in Plain Vanilla Research Limited Partnership (“Fluent”) and the Company’s joint venture with Cannfections Group Inc. (“Cannfections”).

During the three months ended March 31, 2021, the Company made $493 capital contributions to Fluent (2020 - $0). The Company provides production support services to Fluent on a cost recovery basis. For the three months ended March 31, 2021, total fees charged were $372, (2020 - $1,880). The total amount included in accounts payable is $1,785 at March 31, 2021 (December 31, 2020 - $674). At March 31, 2021, the maximum exposure to loss is limited to the Company’s equity investment in Fluent.

During the three months ended March 31, 2021, the Company made $0 capital contributions to Cannfections (2020 - $0). At March 31, 2021, the maximum exposure to loss is limited to the Company’s equity investment in Cannfections. During the three months ended March 31, 2021, the Company incurred $448 in expenses for purchases from Cannfections (2020 - $80).

The Company’s ownership interests in its equity method investments as of March 31, 2020 and December 31, 2019 and loss from equity method investments for the three months ended March 31, 2020 were as follows:

	Approximate	Carrying value		Gain (loss) from equity method investments for the three months ended
	ownership %	March 31, 2021		March 31, 2021
Investment in Fluent	50%	$	4,039	$	(1,802	)
Investment in Cannfections	50%		4,061		15
Total equity method investments		$	8,100	$	(1,787	)

	Approximate	Carrying value		Gain (loss) from equity method investments for the three months ended
	ownership %	December 31, 2020		March 31, 2020
Investment in Fluent	50%	$	5,291	$	(1,819	)
Investment in Cannfections	50%		4,009		71
Total equity method investments		$	9,300	$	(1,748	)

Summary financial information for the equity method investments on an aggregate basis was as follows:

	March 31, 2021		December 31, 2020
Current assets	$	8,440	$	12,644
Noncurrent assets	$	7,033	$	6,608
Current liabilities	$	4,505	$	5,663

	Three months ended March 31,
	2021			2020
Revenue	$	1,061		$	1,392
Gross profit	$	224		$	583
Net loss	$	(3,574	)	$	(3,496	)